JP2023539194A5 - - Google Patents

Info

Publication number
JP2023539194A5
JP2023539194A5 JP2023513110A JP2023513110A JP2023539194A5 JP 2023539194 A5 JP2023539194 A5 JP 2023539194A5 JP 2023513110 A JP2023513110 A JP 2023513110A JP 2023513110 A JP2023513110 A JP 2023513110A JP 2023539194 A5 JP2023539194 A5 JP 2023539194A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
tautomer
pharmaceutically acceptable
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023513110A
Other languages
English (en)
Japanese (ja)
Other versions
JP7743504B2 (ja
JP2023539194A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047754 external-priority patent/WO2022047031A1/en
Publication of JP2023539194A publication Critical patent/JP2023539194A/ja
Publication of JP2023539194A5 publication Critical patent/JP2023539194A5/ja
Priority to JP2025150349A priority Critical patent/JP2025183328A/ja
Application granted granted Critical
Publication of JP7743504B2 publication Critical patent/JP7743504B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023513110A 2020-08-26 2021-08-26 Apol1の阻害剤およびこれを使用する方法 Active JP7743504B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025150349A JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
US63/070,705 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025150349A Division JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Publications (3)

Publication Number Publication Date
JP2023539194A JP2023539194A (ja) 2023-09-13
JP2023539194A5 true JP2023539194A5 (cg-RX-API-DMAC7.html) 2024-08-30
JP7743504B2 JP7743504B2 (ja) 2025-09-24

Family

ID=77822053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513110A Active JP7743504B2 (ja) 2020-08-26 2021-08-26 Apol1の阻害剤およびこれを使用する方法
JP2025150349A Withdrawn JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025150349A Withdrawn JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Country Status (26)

Country Link
US (2) US11866446B2 (cg-RX-API-DMAC7.html)
EP (1) EP4204423B1 (cg-RX-API-DMAC7.html)
JP (2) JP7743504B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230057386A (cg-RX-API-DMAC7.html)
CN (1) CN116547287B (cg-RX-API-DMAC7.html)
AR (1) AR123355A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021333776A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190609A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000536A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023003026A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230132A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000042A (cg-RX-API-DMAC7.html)
EC (1) ECSP23020167A (cg-RX-API-DMAC7.html)
FI (1) FI4204423T3 (cg-RX-API-DMAC7.html)
IL (2) IL300298B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20230035A1 (cg-RX-API-DMAC7.html)
LT (1) LT4204423T (cg-RX-API-DMAC7.html)
MA (1) MA61088B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002269A (cg-RX-API-DMAC7.html)
PE (1) PE20231106A1 (cg-RX-API-DMAC7.html)
PT (1) PT4204423T (cg-RX-API-DMAC7.html)
SA (1) SA523442662B1 (cg-RX-API-DMAC7.html)
TW (1) TWI915407B (cg-RX-API-DMAC7.html)
UY (1) UY39395A (cg-RX-API-DMAC7.html)
WO (1) WO2022047031A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) * 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2024249252A1 (en) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
CN122003420A (zh) 2023-09-11 2026-05-08 弗特克斯药品有限公司 用于制备(2s,4s,4's,6s)-2-甲基-6-(1-甲基-1h-1,2,3-三唑-4-基)-2'-(三氟甲基)-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]-4'-醇的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
WO2003014732A1 (en) 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
AU2004268919A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2178870B1 (en) 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
PL2501704T3 (pl) 2009-11-16 2014-02-28 Lilly Co Eli Spiropiperydynowe związki jako antagoniści receptora ORL-1
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
BR112017007178A2 (pt) 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CA3171950A1 (en) 2020-04-22 2021-10-28 David William Sheppard Collagen 1 translation inhibitors and methods of use thereof
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
PL4129989T3 (pl) 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
AU2022401847A1 (en) 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
EP4476199A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
WO2023154314A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Similar Documents

Publication Publication Date Title
JP2024544060A5 (cg-RX-API-DMAC7.html)
RU2324684C2 (ru) Пиримидиновые производные
RU2326869C2 (ru) Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения
JP2025505644A5 (cg-RX-API-DMAC7.html)
KR890000020B1 (ko) 아릴옥시-및 아릴티오-하이드록시프로필-피페라지닐 아세트아닐리드 및 그의 제조방법
KR101086678B1 (ko) 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법
IL300298B2 (en) Inhibitors of apol1 and methods of using same
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
JP2025505200A5 (cg-RX-API-DMAC7.html)
JP2024543934A5 (cg-RX-API-DMAC7.html)
RU2007141892A (ru) 5-метил-1-(замещенный фенил)-2-(1н)-пиридон для производства медикаментов для лечения фиброза в органах и тканях
JP2005533024A5 (cg-RX-API-DMAC7.html)
JP2020517677A5 (cg-RX-API-DMAC7.html)
JP2025505647A5 (cg-RX-API-DMAC7.html)
JP2019519616A5 (cg-RX-API-DMAC7.html)
JP7604018B2 (ja) 化合物、その薬学的に許容される塩又は立体異性体、及びその使用
CA2405408A1 (en) Pyrazole compounds
US20030087936A1 (en) Imidazolidinone compounds
AU2001246577B2 (en) Pyridazinyl phenyl hydrazones useful against congestive heart failure
JP2023551435A (ja) B型肝炎ウイルス感染症の処置及び予防のためのn置換4-(1,3-アリールオキサゾロ-2-イル)フェニル化合物
JPS6287574A (ja) 新規なn置換3,4−ジヒドロピリミジン−2−オン誘導体、その製造法及び循環器系疾患治療剤
WO2021063852A1 (en) Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
JP2022517984A (ja) 環内チアミジノアミド-アリールアミド系化合物及びb型肝炎を治療するためのその使用
JP2025526864A (ja) 置換1-アリール-1’-ヘテロアリール化合物および置換1,1’-ビヘテロアリール化合物ならびにそれらの類似体の合成
JP2023544446A5 (cg-RX-API-DMAC7.html)